CII
CRL icon

CR Intrinsic Investors’s Charles River Laboratories CRL Stock Holding History

CR Intrinsic Investors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-165,000
Closed -$8.75M – 279
2013
Q4 		$8.75M Buy
+165,000
New +$8.29M 0.38% 91

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

CR Intrinsic Investors's CRL Position: Q1 2014 in Review

CR Intrinsic Investors sold out of Charles River Laboratories (CRL) in Q1 2014, closing a stake of 165,000 shares — an estimated $8.75M sold.

CR Intrinsic Investors first reported a position in CRL in Q4 2013 and held it in 1 quarter. The position peaked at $8.75M in Q4 2013. 258 funds tracked by Wall St. Rank hold CRL as of Q1 2014.

  • CR Intrinsic Investors reported no remaining Charles River Laboratories position as of Q1 2014 after selling out during the quarter.
  • CR Intrinsic Investors sold 165,000 Charles River Laboratories shares in Q1 2014, an estimated $8.75M.
  • CR Intrinsic Investors first reported a position in Charles River Laboratories in Q4 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's Charles River Laboratories position peaked at $8.75M in Q4 2013.
  • 258 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2014.

Based on CR Intrinsic Investors's 13F filing for Q1 2014, filed 15 May 2014.